SPI Infoamtion

このレポートは章ごとの個別販売も行っておりますのでお問い合わせ下さい。
※全てPDFでの販売となります。

Chapter- 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
METHODOLOGY
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter-2: SUMMARY
SUMMARY TABLE GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)
SUMMARY FIGURE GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, 2007--2014 ($ MILLIONS)

Chapter-3: OVERVIEW
INTRODUCTION
OSTEOPOROSIS OVERVIEW
MEDICATION TREATMENT
CLASSIFICATION OF OSTEOPOROSIS DRUGS
Bisphosphonates
SERMs
PTHs
Calcitonins
HRTs
TABLE 1 MARKETED OSTEOPOROSIS DRUGS
DRUG DELIVERY METHODS
Oral Drugs
Injectable Drugs
Nasal Spray and Transdermal Drugs
DRUG DEVELOPMENT PROCESS
INDUSTRY PLAYERS
MAJOR DRUG MANUFACTURERS
SPECIALTY PHARMACEUTICAL COMPANIES
SMALLER COMPANIES
COMPETITIVE FACTORS
SIGNIFICANT TRENDS
GLOBAL AGING POPULATION AND INCREASING LIFE EXPECTANCY TO LEAD TO THE RISING PREVALENCE OF OSTEOPOROSIS
LAUNCH OF NOVEL MECHANISM DRUGS AND IMPROVED FORMULATIONS OF MARKETED DRUGS TO ENHANCE TREATMENT OPTIONS
PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS AND GENERIC DRUG LAUNCHES TO HINDER MARKET GROWTH

Chapter-4: DISEASE OVERVIEW
OSTEOPOROSIS OVERVIEW
OVERVIEW OF THE BONE
BONE STRUCTURE
BONE REMODELING
THE ROLES OF HORMONES IN BONE HEALTH
CLASSIFICATION OF OSTEOPOROSIS
WHO CLASSIFICATION
TABLE 2 WHO CLASSIFICATION OF OSTEOPOROSIS
PRIMARY VERSUS SECONDARY OSTEOPOROSIS
MAYO CLINIC CLASSIFICATION
TABLE 3 MAYO CLINIC CLASSIFICATION OF OSTEOPOROSIS
OSTEOPOROSIS CAUSES AND RISK FACTORS
DIAGNOSIS
OSTEOPOROSIS COMPLICATIONS
DRUG CLASSES APPROVED IN THE TREATMENT OF OSTEOPOROSIS
TABLE 4 OSTEOPOROSIS DRUG CLASSES
BISPHOSPHONATES
SERMS
PTHS
DABAS
CALCITONINS
HRTS
TABLE 5 OSTEOPOROSIS DRUG CLASSES COMPARISON
MEDICATION TREATMENT ALGORITHMS
FIRST LINE OF THERAPY
SECOND LINE OF THERAPY
THIRD LINE OF THERAPY

Chapter-5: PATIENT POPULATION ANALYSIS
OVERVIEW
TABLE 6 OSTEOPOROSIS-RELATED FRACTURES BY PATIENT’S GENDER, 2006 (%)
PATIENT POPULATION CHARACTERISTICS: U.S. AND CANADA
TABLE 7 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: U.S. AND CANADA, 2010 (MILLIONS)
U.S.
TABLE 8 PREVALENCE OF OSTEOPOROSIS IN THE U.S., AGE ? 65 YEARS, 2004 (%)
TABLE 9 U.S. OSTEOPOROSIS-RELATED FRACTURES, 2005
CANADA
PATIENT POPULATION CHARACTERISTICS: EU
TABLE 10 ESTIMATED OSTEOPOROSIS PATIENT POPULATION IN THE EU, 2009 (MILLIONS)
GERMANY
FRANCE
ITALY
SPAIN
U.K.
TABLE 11 U.K. OSTEOPOROSIS-RELATED FRACTURES, 2005
TABLE 12 NUMBER OF HIP FRACTURES PER YEAR IN EU COUNTRIES, 2005
PATIENT POPULATION CHARACTERISTICS: ROW
TABLE 13 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: SELECTED COUNTRIES IN THE ROW, 2009 (MILLIONS)
CHINA
INDIA
JAPAN
LATIN AMERICA

Chapter-6: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS
INDUSTRY STRUCTURE
TIERS OF COMPETITION
TABLE 14 INDUSTRY STRUCTURE: MAJOR COMPETITORS AND MARKETED PRODUCTS
MARKET CONCENTRATION AND PRICE SENSITIVITY
BARRIERS TO ENTRY
Market Saturation and Competitiveness
Sales and Marketing Capabilities
Scientific and Regulatory Challenges in the Development of New Drugs
NOTABLE MERGERS AND ACQUISITIONS
COMPETITIVE FACTORS
PRICE
PRODUCT EFFICACY AND DOSAGE FREQUENCY
DRUG DELIVERY MODE AND CONVENIENCE
SAFETY PROFILE
MARKETING AND SALES EFFECTIVENESS
MARKET CHALLENGES
DISEASE UNDERDIAGNOSIS AND UNDERTREATMENT
POOR PATIENT ADHERENCE TO MEDICATION THERAPY
DRUG REIMBURSEMENT ISSUES
INCREASED SCRUTINY IN THE APPROVAL OF NEW DRUGS
UNMET MARKET NEEDS
IMPROVED ANABOLIC DRUGS
DRUGS WITH SUPERIOR EFFICACY
IMPROVED SIDE EFFECTS AND SAFETY PROFILE DRUGS
IMPROVED DRUG DELIVERY MODALITIES
IMPROVED IDENTIFICATION OF PATIENTS REQUIRING THERAPY
MARKET TRENDS
TABLE 15 MARKET TRENDS IN THE OSTEOPOROSIS MEDICATION MARKET
INCREASED PREVALENCE OF OSTEOPOROSIS AND LIFE EXPECTANCY ARE EXPECTED TO DRIVE MARKET GROWTH GLOBALLY
ENHANCED PATIENT AND PHYSICIAN AWARENESS IS EXPECTED TO LEAD TO EARLIER DISEASE DIAGNOSIS AND TREATMENT
NEW PRODUCT LAUNCHES WITH ENHANCED EFFICACY, CONVENIENCE, AND SAFETY PROFILES ARE EXPECTED TO EXPAND THE MARKET
COST CONSTRAINTS TO AFFECT DRUG CHOICE AND REVENUES
LOSS OF PATENT PROTECTION FOR MAJOR BLOCKBUSTER DRUGS TO SLOW OVERALL MARKET GROWTH
TOTAL MARKET REVENUES AND FORECAST
TOTAL MARKET REVENUES
TABLE 16 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 ($ MILLIONS)
FIGURE 1 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 (%)
MARKET SHARES
TABLE 17 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 2 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
MARKET FORECAST
TABLE 18 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 3 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, 2007--2014 ($ MILLIONS)
Forecast Assumptions
Existing Drug Revenues
Patent Expirations of Major Drugs
Expected New Drug Launches

Chapter-7: MARKETS BY DRUG CLASSES
BISPHOSPHONATES
OVERVIEW
TABLE 19 BISPHOSPHONATES INDUSTRY STRUCTURE, 2009
COMPETITIVE ASPECTS
SAFETY CONCERNS
MARKET REVENUES AND FORECAST
TABLE 20 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY, 2008 (%)
FIGURE 4 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
TABLE 21 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, THROUGH 2014 ($ MILLIONS)
FIGURE 5 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, 2007--2014 ($ MILLIONS)
PRODUCT ANALYSIS
Fosamax
Competitive Aspects
TABLE 22 FOSAMAX ANALYSIS
Actonel
Competitive Aspects
TABLE 23 ACTONEL ANALYSIS
Boniva/Bonviva
Competitive Aspects
TABLE 24 BONIVA/BONVIVA ANALYSIS
Reclast/Aclasta
Competitive Aspects
TABLE 25 RECLAST/ACLASTA ANALYSIS
SERMS
OVERVIEW
TABLE 26 SERM INDUSTRY STRUCTURE, 2009
COMPETITIVE ASPECTS
MARKET REVENUES AND FORECAST
TABLE 27 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 6 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
TABLE 28 GLOBAL SERM MARKET REVENUES, THROUGH 2014 ($ MILLIONS)
FIGURE 7 GLOBAL SERM MARKET REVENUES, 2007--2014 ($ MILLIONS)
PRODUCTS ANALYSIS
Evista
Competitive Aspects
TABLE 29 EVISTA ANALYSIS
PTHS
OVERVIEW
TABLE 30 PTH DRUG INDUSTRY STRUCTURE, 2009
COMPETITIVE ASPECTS
MARKET REVENUES AND FORECAST
TABLE 31 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 8 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
TABLE 32 GLOBAL PTH MARKET REVENUES, THROUGH 2014 ($ MILLIONS)
FIGURE 9 GLOBAL PTH MARKET REVENUES, 2007--2014 ($ MILLIONS)
PRODUCT ANALYSIS
Forteo/Forsteo
Competitive Aspects
TABLE 33 FORTEO ANALYSIS
CALCITONINS
OVERVIEW
TABLE 34 CALCITONINS INDUSTRY STRUCTURE, 2009
COMPETITIVE ASPECTS
MARKET REVENUES AND FORECAST
TABLE 35 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 10 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
TABLE 36 GLOBAL CALCITONINS MARKET, THROUGH 2014 ($ MILLIONS)
FIGURE 11 GLOBAL CALCITONINS MARKET, 2007--2014 ($ MILLIONS)
PRODUCT ANALYSIS
Miacalcin/Miacalcic
Competitive Aspects
TABLE 37 MIACALCIN ANALYSIS
DABAS
OVERVIEW
TABLE 38 DABA INDUSTRY STRUCTURE, 2009
COMPETITIVE ASPECTS
MARKET REVENUES AND FORECAST
TABLE 39 GLOBAL DABA MARKET REVENUES, THROUGH 2014 ($ MILLIONS)
FIGURE 12 GLOBAL DABAS MARKET REVENUES, 2007--2014 ($ MILLIONS)
PRODUCT ANALYSIS
Protelos
Competitive Aspects
TABLE 40 PROTELOS ANALYSIS
HRT
OVERVIEW
TABLE 41 SELECTED MARKETED HRT DRUGS, 2009
COMPETITIVE ASPECTS
MARKET REVENUES AND FORECAST
TABLE 42 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 13 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)
TABLE 43 GLOBAL HRT MARKET, THROUGH 2014 ($ MILLIONS)
FIGURE 14 GLOBAL HRT MARKET, 2007--2014 ($ MILLIONS)
PRODUCTS ANALYSIS
Premarin Line of Products
Competitive Aspects
TABLE 44 PREMARIN PRODUCTS LINE ANALYSIS
EMERGING DRUG CLASSES
OVERVIEW
TABLE 45 EMERGING DRUG CLASSES
PRODUCT ANALYSIS
Prolia
TABLE 46 PROLIA PROFILE
Odanacatib
TABLE 47 ODANACATIB PROFILE
EMERGING DRUG CLASSES FORECAST
TABLE 48 GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, THROUGH 2014 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, 2007--2014 ($ MILLIONS)

Chapter-8: MARKETS BY GEOGRAPHICAL REGIONS
U.S.
MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
Market Overview
TABLE 49 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 16 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
Products
Significant Aspects
REVENUE FORECAST
TABLE 50 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)
FIGURE 17 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, 2007--2014 ($ MILLIONS)
EU
MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
Market Overview
TABLE 51 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 18 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
Products
Significant Aspects
REVENUE FORECAST
TABLE 52 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 ($ MILLIONS)
FIGURE 19 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007--2014 ($ MILLIONS)
ROW MARKET
MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
Market Overview
TABLE 53 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
FIGURE 20 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)
Products
Significant Aspects
REVENUE FORECAST
TABLE 54 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 ($ MILLIONS)
FIGURE 21 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007--2014 ($ MILLIONS)

Chapter-9: PIPELINE REVIEW
PIPELINE OVERVIEW
RANK-LIGAND INHIBITORS
CATHEPSIN K INHIBITORS
SCLEROSTIN INHIBITORS
CALCILYTICS
DKK-1 ANTAGONISTS
DRUGS FILED FOR REGULATORY APPROVAL
PROLIA (DENOSUMAB)
CONBRIZA/VIVIANT (BAZEDOXIFENE)
FABLYN/OPORIA (LASOFOXIFENE)
TABLE 55 OSTEOPOROSIS PIPELINE: DRUGS FILED FOR REGULATORY APPROVAL, 2010
DRUGS IN PHASE III CLINICAL TRIALS
BISPHOSPHONATES
CALCITONINS
CATHEPSIN K INHIBITORS
SERMS/HRTS
PTHS
TABLE 56 GLOBAL PHASE III OSTEOPOROSIS PIPELINE, 2010
DRUGS IN PHASE II CLINICAL TRIALS
BISPHOSPHONATES
BONE MORPHOGENETIC PROTEIN
CALCILYTICS
CALCITONINS
CATHEPSIN K INHIBITORS
DABAS
PTHS
SCLEROSTIN INHIBITORS
TABLE 57 GLOBAL PHASE II OSTEOPOROSIS PIPELINE, 2010
DRUGS IN PHASE I CLINICAL TRIALS
DKK-1 ANTAGONISTS
PTHS
RANK-LIGAND INHIBITORS
SCLEROSTIN INHIBITORS
SRC KINASE INHIBITORS
TABLE 58 GLOBAL PHASE I OSTEOPOROSIS PIPELINE, 2010

Chapter-10: COMPANY PROFILES
ABLYNX NV
AEGIS THERAPEUTICS, LLC
AMGEN, INC.
BONE MEDICAL, LTD.
CHUGAI PHARMACEUTICAL
DAIICHI SANKYO
EFFRX, INC.
ELI LILLY
EMISPHERE TECHNOLOGIES
GLAXO WELLCOME U.K., LTD.
GLAXOSMITHKLINE U.S.
GREEN CROSS CORP.
LES LABORATOIRES SERVIER
MERCK & CO., INC.
MERRION PHARMACEUTICALS
NOVARTIS PHARMA
NOVARTIS CORP.
NOVARTIS PHARMACEUTICALS CORP.
NOVO NORDISK
NPS PHARMACEUTICALS
NYCOMED INTERNATIONAL MANAGEMENT GMBH
OSTEOLOGIX
PFIZER, INC.
PROXIMA CONCEPTS
RADIUS HEALTH
RANBAXY LABORATORIES
ROCHE
HOFFMANN- LA ROCHE PHARMACEUTICALS
SANOFI-AVENTIS
SANOFI-AVENTIS U.S.
TAISHO PHARMACEUTICAL
TEIJIN PHARMA, LTD.
TEIJIN AMERICA, INC.
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
TEVA PHARMACEUTICALS USA
TRANSPHARMA MEDICAL, LTD.
UNIGENE LABORATORIES
WARNER CHILCOTT, PLC
ZELOS THERAPEUTICS, INC.
ZOSANO PHARMA

Chapter-11: NASCENT PATENT APPLICATION ACTIVITY
NASCENT PATENT APPLICATION ACTIVITY